Literature DB >> 8463393

Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children.

M C Steinhoff1, L F Fries, R A Karron, M L Clements, B R Murphy.   

Abstract

Resistance to infection with an influenza A virus conferred by previous infection with an influenza A virus belonging to another subtype is called heterosubtypic immunity. Heterosubtypic immunity is demonstrable in laboratory animals but is believed to be weak in humans. The present study examined whether heterosubtypic immunity from previous influenza virus infection induced resistance to infection with an attenuated influenza A vaccine virus. Two groups of vaccinees consisting of young infants and children who received either influenza A H1N1 or H3N2 attenuated virus were studied. Influenza A H3N2 virus vaccine recipients were classified by their preexisting H1N1 heterosubtypic antibody level induced by prior infection with wild-type virus, and the H1N1 vaccinees were classified by their history of infection with H3N2 vaccine virus. For both groups of vaccinees, the rates of seroconversion and virus shedding and the level of vaccine virus replication were compared in subjects with and without heterosubtypic immunity. In 48 influenza A H3N2 virus and 39 H1N1 virus vaccinees, heterosubtypic immunity had no demonstrable effect on infectivity, immunogenicity, or replication of attenuated vaccine virus. These observations confirm the weak nature of heterosubtypic immunity in humans and suggest that it will not limit the utility of live attenuated influenza A viruses in young infants and children.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8463393      PMCID: PMC263573          DOI: 10.1128/jcm.31.4.836-838.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  Comparison of live attenuated cold-adapted and avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children.

Authors:  M C Steinhoff; N A Halsey; M H Wilson; B A Burns; R K Samorodin; L F Fries; B R Murphy; M L Clements
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

2.  The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children.

Authors:  M C Steinhoff; N A Halsey; L F Fries; M H Wilson; J King; B A Burns; R K Samorodin; V Perkis; B R Murphy; M L Clements
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

3.  Differing virulence of H1N1 and H3N2 influenza strains.

Authors:  P F Wright; J Thompson; D T Karzon
Journal:  Am J Epidemiol       Date:  1980-12       Impact factor: 4.897

4.  Individuals infected with two subtypes of influenza A virus in the same season.

Authors:  A L Frank; L H Taber; J M Wells
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

5.  Heterotypic immunity to influenza in ferrets.

Authors:  R A Yetter; W H Barber; P A Small
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

6.  INDUCTION OF PARTIAL SPECIFIC HETEROTYPIC IMMUNITY IN MICE BY A SINGLE INFECTION WITH INFLUENZA A VIRUS.

Authors:  J L SCHULMAN; E D KILBOURNE
Journal:  J Bacteriol       Date:  1965-01       Impact factor: 3.490

7.  Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses.

Authors:  T Sonoguchi; H Naito; M Hara; Y Takeuchi; H Fukumi
Journal:  J Infect Dis       Date:  1985-01       Impact factor: 5.226

  7 in total
  13 in total

1.  B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms.

Authors:  Javier Rangel-Moreno; Damian M Carragher; Ravi S Misra; Kim Kusser; Louise Hartson; Amy Moquin; Frances E Lund; Troy D Randall
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

Review 2.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

3.  Temporary CXCR3 and CCR5 antagonism following vaccination enhances memory CD8 T cell immune responses.

Authors:  Rui Li; Nan Zhang; Miaomiao Tian; Zihan Ran; Mingjun Zhu; Haiyan Zhu; Fangting Han; Juan Yin; Jiang Zhong
Journal:  Mol Med       Date:  2016-07-06       Impact factor: 6.354

4.  Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus.

Authors:  Ioanna Skountzou; Dimitrios G Koutsonanos; Jin Hyang Kim; Ryan Powers; Lakshmipriyadarshini Satyabhama; Feda Masseoud; William C Weldon; Maria Del Pilar Martin; Robert S Mittler; Richard Compans; Joshy Jacob
Journal:  J Immunol       Date:  2010-06-28       Impact factor: 5.422

5.  Effectiveness of reverse transcription-PCR, virus isolation, and enzyme-linked immunosorbent assay for diagnosis of influenza A virus infection in different age groups.

Authors:  Christoph Steininger; Michael Kundi; Stephan W Aberle; Judith H Aberle; Theresia Popow-Kraupp
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

6.  Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza.

Authors:  B S Bender; C A Rowe; S F Taylor; L S Wyatt; B Moss; P A Small
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

7.  Lung airway-surveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus.

Authors:  Bram Slütter; Lecia L Pewe; Susan M Kaech; John T Harty
Journal:  Immunity       Date:  2013-11-14       Impact factor: 31.745

8.  Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection.

Authors:  Marla Lay; Bernadette Callejo; Stella Chang; David K Hong; David B Lewis; Timothy D Carroll; Shannon Matzinger; Linda Fritts; Christopher J Miller; John F Warner; Lily Liang; Jeffery Fairman
Journal:  Vaccine       Date:  2009-05-09       Impact factor: 3.641

9.  Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains.

Authors:  Y Okuno; K Matsumoto; Y Isegawa; S Ueda
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

10.  Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.

Authors:  T M Tumpey; M Renshaw; J D Clements; J M Katz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.